Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide As First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial

Ying Cheng,Yun Fan,Yanqiu Zhao,Dingzhi Huang,Xingya Li,Peng Zhang,Mafei Kang,Nong Yang,Diansheng Zhong,Zhen Wang,Yan Yu,Yu Zhang,Jun Zhao, Tai Qin, Chenqi Chen,Shiangjiin Leaw,Wenjuan Zheng,Yong Song

JOURNAL OF THORACIC ONCOLOGY（2024）

引用 0|浏览43

暂无评分

关键词

Tislelizumab,Extensive-stage SCLC,Immunotherapy,PD-1

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要